New treatment option for hormon-receptor positive breast cancer approved
On 10.11.2016 Ibrance® (Palbociclib) was approved as new treatment of hormone-receptor positive breast cancer in combination with aromatase inhibitors (Ais) or in combination with fulvestrant. Ibrance® is the first CDK4/6-Inhibitor. The combination therapy with AI/Fulvestrant and Ibrance® had a positive influence in the course of disease in comparison to AI or Fulvestrant mono.
Literature: Finn RS, Martin M, Rugo HS et al. Palbociclib and Letrozole in Advanced Breast Cancer. N Engl J Med. 2016 Nov 17;375(20):1925-1936
Cristofanilli M, Turner NC, Bondarenko I et al.: Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol. 2016 Apr;17(4):425-39. doi: 10.1016/S1470-2045(15)00613-0